Page 1

EPISURF Medical Interim Report 1 January – 31 March 2021 " Whilst this is the best quarter in the history of Episurf , I know that once the Covid - 19 pandemic has subsided , we have much more to look forward to . Of course , we recognise that we are at the start of our financial journey . But showing a strong increase in gross order intake , a growing number of surgeons using the EpisealerⓇ , an improving annual run - rate indicating continued repeat business , and a strong growth in the number of countries in which we are active , during such a challenging quarter as the first quarter of 2021 , gives me a lot of confidence for the future " , says Pål Ryfors , CEO Episurf Medical . First quarter 2021 compared to 2020 , Group >>> Gross order intake amounted to SEK 2.1m ( 1.6 ) , an increase of 30 % . We experienced a 30 % increase in orders for EpisealerⓇ implants during the quarter with 90 ( 69 ) approved orders . Episurf has had the best quarter ever with strong growth in the order book , despite the negative impact of COVID - 19 » Order book amounted to SEK 1.8m ( 1.0 ) , an increase of 71 % » >>> Total income of SEK 1.7m ( 1.6 ) , a growth of 9 % Group net sales increased by 10 % to SEK 1.6m ( 1.5 ) Loss for the period amounted to SEK -16.7m ( -17.9 ) ; The improved result is primarily due to the company's efforts to reduce costs for Europe in connection with the costs of the IDE study increasing and lower costs due to COVID - 19 >>> Earnings per share amounted to SEK -0.08 ( -0.19 ) Significant events during the first quarter » Episurf Medical announced its intention to file a 510 ( k ) application in the US for an EpisealerⓇ Patellofemoral System >>> First EpisealerⓇ Talus surgery in the Asia - Pacific region performed >>> >>> >>> New patents approved in Hong Kong and US for Episurf Medical Episurf Medical entered into distribution agreement for Australia and New Zealand EpisealerⓇ : Clinical results with 5 - years ' follow - up data has been presented at the 3rd World Arthroplasty Congress >>> Clinical results for EpisealerⓇ were accepted for presentation at the 19th ESSKA congress >> Episurf Medical provided COVID - 19 related update ahead of an investor conference Significant events after the first quarter Growth in Q1 , compared to Q1 2020 and Q4 2020 - EpisealerⓇ surgeries booked 30 % vs. Q1 2020 58 % vs. Q4 2020 Growth in Q1 , compared to Q1 2020 and Q4 2020 - Gross order intake 30 % vs. Q1 2020 61 % vs. Q4 2020 Growth in Q1 , compared to Q1 2020 and Q4 2020 - Net sales 9 % 7 % » New patent approved in US for Episurf Medical » Episurf Medical reached milestone of 1,000 implants » Poster with 5 - years ' follow - up data presented at the 3rd World Arthroplasty Congress available vs. Q1 2020 vs. Q4 2020